Autoantibodies against N-homocysteinylated proteins in patients on long-term haemodialysis

Nephrology Dialysis Transplantation

Volumn 22, Issue 6, 2007, Pages 1685-1689

  Undas, Anetta ^a   Kolarz, Marek ^b   Kopeć, Grzegorz ^a   Głowacki, Rafał ^c   Placzkiewicz Jankowska, Ewa ^a   Tracz, Wiesława ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b Haemodialysis Unit Miechow   (Poland)

^c UNIVERSITY OF LODZ   (Poland)

Author keywords

Antibodies; Haemodialysis; Homocysteine; Protein homocysteinylation

Indexed keywords

ACETYLSALICYLIC ACID; ALBUMIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AUTOANTIBODY; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; FOLIC ACID; HEMOGLOBIN; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN G ANTIBODY; IRON; N EPSILON HOMOCYSTEINE; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLIC ACID BLOOD LEVEL; FOLLOW UP; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; IMMUNE RESPONSE; KIDNEY FAILURE; LONG TERM CARE; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; AUTOANTIBODIES; CORONARY ARTERIOSCLEROSIS; FEMALE; HEMOGLOBINS; HOMOCYSTEINE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RENAL DIALYSIS; SERUM ALBUMIN; TIME FACTORS;

EID: 34347224500     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfm068     Document Type: Article

References (23)

1. Manns BJ, Burgess ED, Hyndman ME et al. Hyperhomocyst(e)inemia and the prevalence of atherosclerotic vascular disease in patients with end-stage renal disease. Am J Kidney Dis 1999; 34: 669-677
2. Bostom AG, Shemin D, Verhoef P et al. Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients. Arterioscler Thromb Vasc Biol 1997; 17: 2554-2558
3. Mallamaci F, Zoccali C, Tripepi G et al. Hyperhomocysteinemia predicts cardiovascular outcomes in haemodialysis patients. Kidney Int 2002; 61: 609-614
4. Gupta R, Birnbaum Y, Uretsky BF. The renal patient with coronary artery disease: Current concepts and dilemmas. J Am Coll Cardiol 2004; 44: 1343-1353
5. van Guldner C. Why is homocysteine elevated in renal failure and what can be expected from homocysteine-lowering? Nephrol Dial Transplant 2006; 21: 1161-1166
6. Perna AF, Ingrosso D, Lombardi C et al. Possible mechanisms of homocysteine toxicity. Kidney Int 2003; 84: S137-S140
7. Jakubowski H, Zhang L, Bardeguez A, Aviv A. Homocysteine thiolactone and protein homocysteinylation in human endothelial cells: Implications for atherosclerosis. Circ Res 2000; 87: 45-51
8. Schroecknadel K, Frick B, Winkler C et al. Hyperhomocysteinemia and immune activation. Clin Chem Lab Med 2003; 41: 1438-1443
9. Jakubowski H. Anti-N-homocysteinylated protein autoanti-bodies and cardiovascular disease. Clin Chem Lab Med 2005; 43: 1011-1014
10. Jakubowski H. Protein homocysteinylation: Possible mechanism underlying pathological consequences of elevated homocysteine levels. FASEB J 1999; 13: 2277-2283
11. Uji Y, Motomiya Y, Hanyu N et al. Protein-bound homocystamide measured in human plasma by HPLC. Clin Chem 2002; 48: 941-944
12. Glowacki R, Jakubowski H. Cross-talk between Cys-34 and lysine residues in human serum albumin revealed by N-homocysteinylation. J Biol Chem 2004; 279: 10864-10872
13. Undas A, Perla J, Lacinski M et al. Autoantibodies against N-homocysteinylated proteins in humans: Implications for atherosclerosis. Stroke 2004; 35: 1299-1304
14. Undas A, Jankowski M, Twardowska M et al. Autoantibodies to N-homocysteinylated albumin as a marker for early-onset coronary artery disease in men. Thromb Haemost 2005; 93: 346-350
15. Perna AF, Satta E, Acanfora F et al. Increased plasma protein homocysteinylation in hemodialysis patients. Kidney Int 2006; 69: 869-876
16. Araki A, Sako Y. Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection. J Chromatogr 1987; 422: 43-52
17. Daugirdas JT. Second generation logarithmic estimates of single-pool variable-volume kt/V: An analysis of error. J Am Soc Nephrol 1993; 4: 1205-4213
18. Jakubowski H. Homocysteine is a protein amino acid in humans: implications for homocysteine-linked disease. J Biol Chem 2002; 277: 30425-30428
19. Kraus LM, Kraus AP, Jr, Carbamoylation of amino acids and proteins in uremia. Kidney Int Suppl 2001; 78: S102-107
20. Dantoine TF, Debord J, Charmes JP et al. Decrease of serum paraoxonase activity in chronic renal failure. J Am Soc Nephrol 1998; 9: 2082-2088
21. Gonin JM, Nguyen H, Gonin R et al. Controlled trials of very high dose folic acid, vitamins B12 and B6, intravenous folinic acid and serine for treatment of hyperhomocysteinemia in ESRD. J Nephrol 2003; 16: 522-534
22. Undas A, Stepien E, Glowacki R, Tisonczyk J, Tracz W, Jakubowski H. Folic acid administration and antibodies against homocysteinylated proteins in subjects with hyperhomocysteinemia. Thromb Haemost 2006; 96: 342-347
23. Locatelli F, Canaud B, Eckatelli L et al. Oxidative stress in endstage renal disease: An emerging threat to patient outcome. Nephrol Dial Transplant 2006; 18: 1272-1280